The FDA will decide on new drugs for rosacea, AADC deficiency, breast cancer, transthyretin amyloid cardiomyopathy, and biliary tract cancer.

Pacylex was recognized as BioAlberta's 2024 Company of the Year. The award acknowledges a company that has shown significant achievement within the marketplace and Alberta's business community through ...

Department of Lung Cancer and Thoracic Tumors, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland A substantial portion of patients with advanced cancer cannot be cured, ...

Most of the chemotherapeutic agents are unable to penetrate the blood–brain barrier. EGF receptor (EGFR) tyrosine kinase inhibitors (TKIs), given their low molecular weight, may be able to reach ...

Rybrevant plus Lazcluze, compared with Tagrisso, showed a trend towards favorable overall survival in EGFR-positive advanced non-small cell lung cancer. In the first line of treatment, Rybrevant ...

These cytokines bind heterodimer receptors to activate three major signaling pathways: MAPK, PI3K, and JAK/STAT. This perspective will look at the mechanisms of these three pathways in microglia and ...

Peter Lawson has given his Buy rating due to a combination of factors including Relay Therapeutics’s promising data on PI3K inhibitors in advanced breast cancer. The clinical trials indicated a ...

In first-line metastatic NSCLC patients with EGFR PACC mutations, the overall response rate by blinded independent central review was 81.8% (n=22; 95% CI, 59.7–94.8%) for those receiving the 240 ...

The recent FDA approval of Lazcluze plus Rybrevant for EGFR-mutant non-small cell lung cancer is a “big deal” for patients, an oncologist said. Patients with EGFR-mutant non-small cell lung cancer ...

Inavolisib is a small molecule commercialized by Roche, with a leading Pre-Registration program in Human Epidermal Growth Factor Receptor 2 Negative Breast ... It acts by targeting ...